Prevalence of Faecal Bacteriophage in Patients With Digestive Symptoms
NCT ID: NCT06524791
Last Updated: 2024-07-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
300 participants
OBSERVATIONAL
2024-11-15
2025-11-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
(ii) Determine fecal phage genome concentrations in the stools of individuals with digestive symptoms (PCR detection)
(iii) Explore factors that could impact fecal phage carriage (patients with digestive symptoms vs. healthy individuals, immunocompromised patients vs. immunocompetent patients)
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
SARS-CoV-2 in Stools Compared to Respiratory Viral Strains.
NCT05567419
Study of the Interactions Between Dientamoba Fragilis and the Gut Microbiota
NCT02534272
Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections
NCT01232595
Search Cytomegalovirus in Healthy Volunteers Stools Samples Selected as Potential Donor for Fecal Microbiota Transplant
NCT02694484
Investigation of the Detection Rate of Pathogenic Viruses in the Feces of Individuals With Non-gastrointestinal Infections
NCT06367647
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
immunocompetent
immunocompetent patients with digestive symptoms (n=150)
bacteriophage detection
bacteriophage detection
immunocompromised
immunocompromised patients with digestive symptoms (n=150)
bacteriophage detection
bacteriophage detection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
bacteriophage detection
bacteriophage detection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Persons having developed gastrointestinal symptoms justifying microbiological stool testing at the time of hospitalization.
* Person having received full information on the organization of the research and not having objected to the use of this data
Exclusion Criteria
* Pregnant or breast-feeding women,
* Minors (not emancipated),
* Adult subject to a legal protection measure (guardianship, curatorship, safeguard of justice),
* Persons of full age who are unable to give their consent.
* Persons deprived of their liberty by a judicial or administrative decision, persons under psychiatric care by virtue of articles L. 3212-1 and L. 3213-1.
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Central Hospital, Nancy, France
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
HARTARD Cédric
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Cédric Hartard
Role: PRINCIPAL_INVESTIGATOR
CHRU Nancy
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHRU Nancy
Nancy, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-0323
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.